Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Oct 27.

Published in final edited form as: J Cardiovasc Pharmacol Ther. 2018 Mar 19;23(4):350–357. doi: 10.1177/1074248418763612

Table 1.

Hemodynamic Parameters.^a

		Baseline				End of perfusion
	n	HR, bpm	LVDP, cmH₂O	RPP (LVDP × HR)	CF, mL/min	HR, bpm	LVDP, cmH₂O	RPP (LVDP × HR)	CF, mL/min

Control (DMSO)	3	372 ± 6	118 ± 7	44 093 ± 3094	3.0 ± 0.5	344 ± 9	112 ± 5	38 576 ± 2612	2.9 ± 0.4
PFT-α 2.5 μmol/L	3	350 ± 19	117 ± 5	41 225 ± 3433	3.1 ± 0.4	336 ± 33	110 ± 6	36 926 ± 5104	2.8 ± 0.3
PFT- α 10 μmol/L	4	351 ± 27	118 ± 5	41 648 ± 4835	2.5 ± 0.4	201 ± 28^b	77 ± 14^b	16 238 ± 4489^b	1.7 ± 0.3^b
PFT-μ 25 μmol/L	4	352 ± 10	114 ± 5	40 094 ± 1700	2.4 ± 0.3	342 ± 5	118 ± 6	40 090 ± 1850	2.4 ± 0.1

Abbreviations: HR, heart rate; LVDP, left ventricular developed pressure; RPP, rate pressure product; CF, coronary flow; PFT, pifithrin.

^a

Data are mean + SEM. End of perfusion = 15 minutes after perfusion with each drug.

^b

P < 0.05 vs Control (DMSO).